^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Source:
Title:
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Excerpt:
...- Have written documentation of local laboratory or central laboratory determination of a known or likely activating FGFR2 fusion/rearrangement from a sample collected before randomization...
Trial ID:
Source:
Title:
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Excerpt:
...Written documentation of local or central laboratory determination of amplification or translocation to FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1, FGFR2,or FGFR3 3....
Trial ID:
Less C2 evidence
Source:
Title:
Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
Excerpt:
Clinically, in an open-label phase II trial, infigratinib demonstrated a confirmed overall response rate (cORR) of 39.3% in FGFR2 fusion-positive cholangiocarcinoma patients who received infigratinib as second-line therapy (Figure 7). Additionally, clinical benefit was observed in...solid tumors tested positive for FGFR fusions.
